Todovichin Donika1, 2, Petar Trifonov1, 2, *, Deyan Jelev1, 2, Krasimir Antonov1, 2, Rosen Nikolov1, 2
1Clinic of Gastroenterology, UMHAT St. Ivan Rilski, Sofia, Bulgaria - 2Department of Internal Medicine, Faculty of Medicine, Medical University-Sofia
Introduction: Chronic hepatitis B infection remains a global health challenge, with nucleotide/nucleoside analogs (NUCs) as a primary treatment option.
Materials and methods: A retrospective analysis was conducted on 337 patients treated with NUCs over a 5-year period. Quantitative HBsAg values were determined at baseline and at 3 and 5 years after starting the treatment. Quantitative HBsAg values were determined at the beginning, prior to initiating antiviral therapy, and at 3 and 5 years after starting the treatment.
Results: The results demonstrated a significant association between quantitative HBsAg values and liver cirrhosis, with higher baseline values observed in patients with cirrhosis. Furthermore, a faster decline in HBsAg titer during treatment was observed in HBeAg-positive patients compared to HBeAg-negative patients.
Conclusion: Our findings support the use of quantitative HBsAg as an important marker for monitoring liver disease progression and individual risk assessment in chronic hepatitis B patients treated with NUCs. Further research is needed to optimize treatment strategies based on quantitative HBsAg levels and other surrogate markers.
Hepatitis B, HBsAg, therapy, NUC, decline.